To further verify the rationality of Egr-1 to be used as an impactive target in the treatment of MS, we examined the first-line drugs currently used in the clinical treatment of MS, including glatiramer acetate (GA; 0.15 mg/mouse), fingolimod (FTY-720; 1 mg/kg), IFN-β (1 × 104 U/mouse), and dexamethasone (DEX; 0.07 mg/mouse) in terms of Egr-1 activation. The gene discussed is EGR1; the disease is myeloid sarcoma.